February 7, 2018 / 1:39 PM / 5 months ago

BRIEF-Therapix Biosciences Expects To Test THX-110 In Early Study In Q2

Feb 7 (Reuters) - Therapix Biosciences Ltd:

* THERAPIX BIOSCIENCES LTD - EXPECT TO EVALUATE THX-110 IN A PHASE IIB CLINICAL STUDY IN Q2 OF 2018

* THERAPIX BIOSCIENCES - COMPLETES PRE-IND COMMUNICATION WITH FDA ON THX-110 FOR TOURETTE SYNDROME: CLINICAL DEVELOPMENT TO PROCEED AS PROJECTED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below